Philine van den Tol | CEO ad interim

News

|

Hanka van de Merwe

It’s with gratitude that iClusion has welcomed Philine van den Tol asCEO ad interim, per May 2022. Ms. Philine van den Tol is a senior executive and entrepreneur with over25 years of experience in the life science industry. She served as ChiefExecutive Officer of SMS-oncology, where she built and led one of the world’s boutique clinical research organizations solely dedicated to oncology. After a successful merger with CATO, a CRO in the United States, Philine became the President Clinical Trial Operations of CATO SMS (now Allucent), having globalresponsibility and executive oversight for clinical trial operations. In parallel she served as Managing Director of CATO SMS’ headquarters in Amsterdam.

Edwin Klumper, founder and member of the board says; “With Philine’s in-depth knowledge of the industry, entrepreneurial sense and vast experience as an executive leader, we are excited to have her on board to support our mission”.  

Philine: "I am honored to be part of such an ambitious organization and team. If we want to make new innovative cancer treatments available, it is essential to bridge the gap between clinical trials and patients. It is a wonderful opportunity for me contributing to that".

For any media related questions please send us a message.

Press release Philine van den Tol appointed as CEO ad interim at iClusion

Janssen Roepman Oncologie UpToDate sept2018

You might also like these articles

Latest update July 2022

July 4, 2022

News

Read all about the latest highlights and planned activities here.

Philine van den Tol | CEO ad interim

May 30, 2022

News

Philine van den Tol appointed as CEO ad interim

iClusion presenting Heyleys on Dutch oncology days 2022

May 20, 2022

News

Visit us | Heyleys Stand nr. 19 at the Dutch Oncology days in Ede location Reehorst.